Skip To Main Content
Alexey Maslyanskiy on Muck Rack

Alexey Maslyanskiy

As seen in: JACC (Journal of the American College of Cardiology), Multiple Sclerosis and Related Disorders
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Alexey Maslyanskiy’s profile

Articles by Alexey Maslyanskiy

Treatment of Idiopathic Recurrent Pericarditis With Goflikicept: Phase II/III Study Results

|
By Alexey Maslyanskiy, Olga Moiseeva, Valentina Yu. Myachikova, Oksana V. Vinogradova
| JACC (Journal of the American College of Cardiology)
JACC Journals › JACC › Archives › Vol. 82 No. 1 Abstract Background Idiopathic recurrent pericarditis (IRP) is a rare autoinflammatory disease. Interleukin (IL)-1α and IL-1β are the pivotal cytokines in the pathophysiology of acute pericarditis and its recurrence. We created a phase II/III study with a new IL-1 inhibitor—goflikicept in IRP. Objectives This study sought to evaluate the efficacy and safety of goflikicept treatment in patients with IRP.
Open in Who Shared Issue with article?

The effects of intrathecal rituximab on biomarkers in multiple sclerosis

|
By Ruth Dobson, Sergey V. Lapin, Joanne Topping, Alexey Maslyanskiy
| Multiple Sclerosis and Related Disorders Verified
Highlights • Despite intrathecal administration, rituximab was detectable in the serum but not the CSF. • CSF BAFF fell following rituximab administration, but serum BAFF increased. • Serum CD20+ and CD19+ cell populations fell in the peripheral blood compartment following rituximab administration. Abstract Objectives Clinical trials of IV-rituximab have proved successful. It is unclear whether intrathecal (IT)-rituximab is more efficacious at lower doses. We examine its effects on B-cell biomarkers.
Open in Who Shared Issue with article?
Show More